Pfizer Inc. (NYSE: PFE) has initiated a phase 3 clinical program for its investigational 25-valent pneumococcal conjugate vaccine candidate following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE